RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED DOSE ESCALATION STUDY OF ULARITIDE FOLLOWED BY A 42-HOUR INFUSION FOR THE TREATMENT OF ACUTE KIDNEY INJURY (AKI) IN PATIENTS POST CARDIAC SURGERY - TRUST

开始日期2019-09-05

申办/合作机构

Cardiorentis AG

NCT01661634 / Completed临床3期

Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Ularitide (Urodilatin) Intravenous Infusion in Patients Suffering From Acute Decompensated Heart Failure [TRUE-AHF]

The purpose of this study is to evaluate the efficacy and safety of a continuous intravenous (IV) ularitide infusion on the clinical status and outcome of patients with acute decompensated heart failure (ADHF).

开始日期2012-07-01

申办/合作机构

Cardiorentis AG

[+1]

100 项与 Cardiorentis AG 相关的临床结果

登录后查看更多信息

0 项与 Cardiorentis AG 相关的专利（医药）

登录后查看更多信息

项与 Cardiorentis AG 相关的文献（医药）

2006-10-27·European journal of medical research

ANP and urodilatin: who is who in the kidney.

Review

作者: Meyer, Markus ; Hirsch, J R ; Forssmann, W-G

Mounting evidence suggests that urodilatin, not atrial natriuretic peptide (ANP) is the responsible peptide in regulation of renal Na superset+- and water homeostasis. Following the discovery of ANP this peptide was thought to be responsible for the induction of natriuresis and diuresis in the mammalian kidney. However, the isolation of urodilatin from human urine and substantial work contributed to a better understanding of the renal physiology of these two natriuretic peptides. Indeed, subsequent elucidation supported that urodilatin rather than ANP seems to be the natriuretic peptide responsible for the regulation of Na superset+- and water homeostasis in the kidney. Urodilatin - synthesized and secreted from the distal tubules of the kidney - may act as a paracrine mediator when secreted into the lumen. In contrast, while the role of ANP as regulator of the cardiovascular system is established, its physiological regulatory role on transport processes in the nephron is questionable. This review attempts to analyze the roles of both ANP and urodilatin and to discuss new potential candidates which may also play a role in electrolyte and water handling in the kidney.

2001-01-01·New Drugs for Asthma, Allergy and COPD

作者: Meyer, Markus ; Forssmann, Wolf Georg ; Forssmann, Kristin

A review with 25 referencesUrodilatin (INN: Ularitide) belongs to the family of natriuretic peptides.Results indicate that urodilatin is synthesized in kidney tubular cells and secreted luminally because this peptide is found solely in urine and not in blood plasma.In its natural function, urodilatin plays the role of a paracrine regulator for sodium and water homeostasis in the kidney.Since the discovery of urodilatin in 1988, a vast number of pharmacol. and clin. investigations have been carried out.To date more than 1,000 patients have been treated with urodilatin for indications such as acute renal failure, congestive heart failure and bronchial asthma in clin. phase I and II studies.

Renal natriuretic peptide system and actions of urodilatin

作者: Meyer, Markus ; Hirsch, Jochen R. ; Forssmann, Wolf-Georg

A review.Urodilatin, a natriuretic peptide with four addnl. amino acids compared to atrial natriuretic peptide (ANP), is generated in distal tubule cells of the renal nephron.Whereas the fundamental role of ANP in the kidney, namely the regulation of natriuresis and diuresis, is questionable, urodilatin may be responsible for this task when secreted into the lumen of the distal tubule.More stable than ANP, it can act as a paracrine regulator and bind to its specific receptors located in the luminal membrane of cortical collecting duct (CCD) and inner medullary collecting duct (IMCD), thus, displaying its effects on cellular pH, Na⁺ transport, and H₂O homeostasis.Urodilatin might also play a future role in the treatment of acute decompensated heart failure, acute renal failure, and bronchial asthma.

项与 Cardiorentis AG 相关的新闻（医药）

2024-03-02

·PRNewswire

Global Acute Heart Failure (AHF) Therapeutics Research Report 2022-2024 and 2030: Conventional Therapies Leave Considerable Unmet Needs, Novel Treatments Offer a Ray of Hope

DUBLIN, March 1, 2024 /PRNewswire/ -- The "Acute Heart Failure (AHF) Therapeutics: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. Global Acute Heart Failure (AHF) Therapeutics Market to Reach $2.9 Billion by 2030 The global market for Acute Heart Failure (AHF) Therapeutics estimated at US$599.7 Million in the year 2022, is projected to reach a revised size of US$2.9 Billion by 2030, growing at a CAGR of 21.7% over the analysis period 2022-2030. Cardiac Glycosides, one of the segments analyzed in the report, is projected to record a 22.3% CAGR and reach US$762.4 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the B-Blockers segment is readjusted to a revised 25.1% CAGR for the next 8-year period. The acute heart failure (AHF) market has been significantly impacted by the COVID-19 pandemic and the looming global recession. Despite the challenges, diuretics and vasodilators remain the first-line therapy for AHF, although the efficacy of other known drugs for AHF is limited, hindering their widespread use. Market insights and trajectories indicate a complex landscape influenced by these factors, with varying degrees of competitive market presence among players worldwide in 2022. Recent market activity reflects ongoing efforts to size the AHF market and adapt to the evolving healthcare landscape. Looking ahead, the market outlook suggests continued focus on addressing the challenges posed by COVID-19 and economic uncertainties while exploring opportunities for innovation and growth in AHF therapeutics. The U.S. Market is Estimated at $163.4 Million, While China is Forecast to Grow at 30.4% CAGR The Acute Heart Failure (AHF) Therapeutics market in the U.S. is estimated at US$163.4 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$841.2 Million by the year 2030 trailing a CAGR of 30.4% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 16.3% and 18.4% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 17.1% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$433.4 Million by the year 2030. MARKET OVERVIEW Influencer Market Insights World Market Trajectories Market Outlook Recent Market Activity Sizing the AHF Market Acute Heart Failure - An Overview of the Disease and Available Therapeutics Diuretics and Vasodilators - The First Line Therapy for AHF Other Known Drugs for AHF - Lower Efficacy Thwarts Use Acute Heart Failure (AHF) Therapeutics - Global Key Competitors Percentage Market Share in 2022 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E) Impact of Covid-19 and a Looming Global Recession MARKET TRENDS & DRIVERS Conventional Therapies Leave Considerable Unmet Needs Novel Treatments Offer a Ray of Hope Key AHF Therapeutics in the Pipeline Serelaxin Nears Trial Readout form RELAX-AHF-2 Ularitide - A Novel Drug in Development for AHF The Litany of Drug Failures Expands, Emphasis on Prevention Grows Other Promising Drugs under Development Research Findings Kidney Dysfunction - Predictor of Acute Heart failure Genetic Influence on Heart Disease among African Americans Higher Body Mass Index - A Key Risk Factor for AHF Supplemental Oxygen Therapy May not be for All Cases of AHF Macro Growth Drivers Alarming Levels of Cardiovascular Disease (CVD) Prevalence: Key Growth Driver for AHF Therapeutics Ballooning Elderly Population: The Vital Growth Driver for AHF Therapeutics FOCUS ON SELECT PLAYERS (Total 93 Featured) Bayer AG (Germany) Bristol-Myers Squibb Company (USA) Cardiorentis AG (Switzerland) CVie Therapeutics Limited (Taiwan) Cytokinetics, Inc. (USA) Merck & Co. (USA) Novartis AG (Switzerland) Orion Corporation (Finland) PhaseBio Pharmaceuticals, Inc. (USA) For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

AHA会议

100 项与 Cardiorentis AG 相关的药物交易

登录后查看更多信息

100 项与 Cardiorentis AG 相关的转化医学

登录后查看更多信息